B. Sicilia et al., High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy, MED CLIN, 115(17), 2000, pp. 641-643
BACKGROUND: To analyze the effectiveness of a second-line treatment of Heli
cobacter pylori infection in patients with duodenal ulcer based on previous
antibiotic regimen.
PATIENTS AND METHODS: Open, prospective, uncontrolled study, but guided by
protocol including 30 consecutive patients with endoscopic diagnosis of act
ive duodenal ulcer and failure of a first-line H. pylori eradication treatm
ent diagnosed by urea breath test or a new endoscopy with histology and pos
itive urease test. Treatment consisted in 10 days-with omeprazole (20 mg/12
h), bismuth subcitrate (120 mg/6 h), tetracycline (500 mg/6 h) and metroni
dazole (500 mg/8 h) (OBTM) if previous regimen was with clarithromycin; or
10 days with omeprazole (20 mg/12 h), clarithromycin (500 mg/12 h) and amox
ycillin (1g/12 h) (OCA) if previous regimen did not include clarithromycin;
using metronidazole (500 mg/8 h) instead of amoxycillin (OCM) in case of a
llergy. Eradication was defined as a negative C-13-urea breath test 2 month
s after the end of therapy.
RESULTS: One patient had to stop treatment due to the side effects and in 2
patients urea breath test was not performed (3 patients due to the OBTM gr
oup). Per protocol eradication was achieved in 25 out of 27 patients (92.6%
) and by intention-to-treat eradication was attained in 25 out of 30 cases
(83.3%). When both groups analyzed separaty, the OCA combination was succes
sful in 5 from 6 patients (83.3%; 95% CI 35.9-99.6); while the OBTM combina
tion was successful in 20 from 21 valuable patients (95.2%; 95% CI 76.2-99.
9). In this second case we make an intention to treat analysis and eradicat
ion was achieved in 20 from 24 (83.3%; 95% Ct 62.6-95.3).
CONCLUSION: The eradicative treatment for H. pylori based in different anti
biotics used in subsequent attempts get high eradication rates in patients
with duodenal ulcer.